Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (ATNM)
1.3100
+0.0400 (3.15%)
NYSE · Last Trade: Apr 26th, 2:55 PM EDT
Detailed Quote
Previous Close
1.270
Open
1.230
Bid
1.250
Ask
1.270
Day's Range
1.211 - 1.360
52 Week Range
1.029 - 10.24
Volume
324,480
Market Cap
27.94M
PE Ratio (TTM)
-1.031
EPS (TTM)
-1.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,105,190
Chart
About Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (ATNM)
Actinium Pharmaceuticals Inc is a biotechnology company that focuses on the development of innovative therapies for cancer treatment. The company's primary emphasis is on harnessing the power of targeted radiotherapy, utilizing its proprietary platform to create treatments that deliver radiation directly to cancer cells while minimizing damage to surrounding healthy tissue. By advancing its pipeline of both therapeutic and diagnostic candidates, Actinium aims to improve patient outcomes in hematologic cancers and solid tumors, contributing to the overall evolution of cancer care. The company's efforts are geared towards addressing unmet medical needs in oncology and enhancing the effectiveness of existing treatment modalities. Read More
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Actinium To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Solaris Energy Infrastructure, Inc. (NYSE: SEI), Actinium Pharmaceuticals, Inc. (NYSE:ATNM), Bakkt Holdings, Inc. (NYSE:BKKT), and Cerevel Therapeutics Holdings, Inc. (CERE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Actinium To Contact Him Directly To Discuss Their Options
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Solaris Energy Infrastructure, Inc. (NYSE: SEI), Actinium Pharmaceuticals, Inc. (NYSE:ATNM), Bakkt Holdings, Inc. (NYSE:BKKT), and Cerevel Therapeutics Holdings, Inc. (CERE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options
Scott+Scott Attorneys at Law LLP (“Scott+Scott”) issues this corrected notice to clarify the deadline to seek appointment as Lead Plaintiff in the securities class action against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) and other defendants. On March 27, 2025, Scott+Scott filed a securities class action lawsuit in the United States District Court for the Southern District of New York against Actinium (NYSE American: ATNM), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. §240.10b‑5) on behalf of all persons other than Defendants who purchased or otherwise acquired Actinium securities between October 31, 2022, and August 2, 2024, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Scott+Scott is captioned: Kohil v. Actinium Pharmaceuticals, Inc., et al., Case No. 1:25-cv-02553. On March 27, 2025, Scott+Scott published a notice which inadvertently stated that the deadline to seek appointment as Lead Plaintiff is May 26, 2025. Pursuant to the March 27, 2025 notice published in connection with the Action, however, under the Private Securities Litigation Report Act of 1995, investors who purchased or otherwise acquired Actinium securities during the Class Period may, no later than May 27, 2025, seek to be appointed as Lead Plaintiff for the Class. Any member of the proposed Class may seek to serve as Lead Plaintiff through counsel of their choice or may choose to do nothing and remain a member of the proposed Class.
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE: ATNM) and certain of its officers.
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE:ATNM) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Actinium securities between October 31, 2022, and August 2, 2024, both dates inclusive (the “Class Period”). Investors have until May 26, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) investors concerning the Company’s possible violations of federal securities laws.
NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024. Actinium describes itself as a “late-stage biopharmaceutical company that develops targeted radiotherapies.”
The Law Offices of Frank R. Cruz announces an investigation of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) on behalf of investors concerning the Company’s possible violations of federal securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE American: ATNM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. §240.10b-5) on behalf of all persons other than Defendants who purchased or otherwise acquired Actinium securities between October 31, 2022, and August 2, 2024, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Scott+Scott is captioned: Kohil v. Actinium Pharmaceuticals, Inc., et al., Case No. 1:25-cv-02553.
